Effects of aminaftone 75 mg TID on soluble adhesion molecules: A 12-week, randomized, open-label pilot study in patients with systemic sclerosis

Scorza, Raffaella; Santaniello, Alessandro; Salazar, Giulia; Lenna, Stefania; Bella, Silvia Della; Antonioli, R.; Toussoun, Karen; Beretta, Lorenzo

doi:10.1016/j.clinthera.2008.05.009

Cited by 15 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have reported that aminaphtone reduces vessel permeability and tissue oedema (De Anna et al, 1989; Scorza et al, 2008a,b). Furthermore, results from in vitro studies suggest that among different mechanisms of action, aminaphtone may down-regulate the E-selectin (ELAM-1), Vascular Cell Adhesion Molecule-1 (VCAM-1) and Intra Cellular Adhesion Molecule-1 (ICAM-1) expression, as well as cytokine/chemokine and endothelin-1 production on cultured human endothelial cells (Scorza et al, 2008a,b; Salazar et al, 2016). Of note, endothelin-1 generates vasoconstriction on microvessels and its serum level is increased in both patients with primary and secondary RP (Sulli et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon: A Feasibility Study

et al. 2019

View full text Add to dashboard Cite

Objectives The aim of this six-month open feasibility study was to evaluate skin blood perfusion and clinical symptom changes during aminaphtone treatment in patients with either primary or secondary Raynaud’s phenomenon to systemic sclerosis. Methods Ninety-two patients referring for Raynaud’s phenomenon have been enrolled in November during routine clinical assessment, after informed consent. Aminaphtone was administered 75 mg twice daily in addition to current treatments to forty-six patients. Skin blood perfusion was measured by Laser Speckle Contrast Analysis (LASCA) at the level of fingertips, periungual areas, dorsum and palm of hands, and face at baseline (W0), after one (W1), four (W4), twelve (W12) and twenty-four (W24) weeks of treatment. Raynaud’s condition score (RCS) and both frequency and duration of Raynaud’s attacks were assessed at the same time. Results Compared with the control group, despite colder period of the year, aminaphtone treated patients showed a progressive statistically significant increase of blood perfusion, as well as a decrease of RCS, frequency of Raynaud’s attacks/day and their duration, from W0 to W12 in all skin areas. From W12 to W24 no further increase of blood perfusion was observed. The results were similar in both primary and secondary Raynaud’s phenomenon patients. Five weeks after aminaphtone discontinuation blood perfusion values were significantly higher than those at baseline in the majority of skin areas. Conclusion This study demonstrates that aminaphtone treatment increases skin blood perfusion and improves Raynaud’s phenomenon clinical symptoms, with sustained efficacy up to 6 months, even in patients with systemic sclerosis. A randomized, blind, controlled, clinical trial including a larger number of subjects is advisable to confirm these early results.

show abstract

Section: Discussionmentioning

confidence: 99%

Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon: A Feasibility Study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A preliminary in vitro study suggested that aminaphtone, a naphthohydrochinon used in the treatment of capillary disorders, may downregulate the expression of adhesion molecules in endothelial cells. In a pilot study of a select group of patients with systemic sclerosis, aminaphtone was associated with the downregulation of sELAM-1 and sVCAM-1 concentrations [10]. …”

Section: Discussionmentioning

confidence: 99%

Aminaphtone for Light Bleeding in Patients Under Oral Anticoagulation

Godoy

Paludetto²,

Testoni³

et al. 2010

TOCMJ

View full text Add to dashboard Cite

Background:Bleeding is a common complication of oral anticoagulation therapy. Objective: The present study evaluated the use of aminaphtone in patients with minor bleeding while taking warfarin. Methods:Seven patients suffering from bleeding of the nose and gums, who were taking therapeutic doses of warfarin, were included in the study. Results:The patients were prescribed 75 mg aminaphtone twice daily. For 5 of these patients the bleeding was controlled within 48 h, for 1, within 96 h and for the other, a satisfactory reduction was obtained. Conclusion:Patients with minor bleeding during treatment using oral anticoagulation, who are free from risk of other complications, can benefit from the use of aminaphtone as an initial therapeutic option.

show abstract

“…It has also been used for chronic epistaxis and for bleeding episodes associated with the use of warfarin or blood loss due to dental extraction. 24 Aminaphtone also down-regulates adhesion factors, 25 a property, which suggests might be useful for sclerodermal disease. 17 …”

Section: Aminaphtonementioning

confidence: 98%

Prevention of Excessive Endothelin-1 Release in Sclerotherapy

Duffy

2014

Dermatologic Surgery

View full text Add to dashboard Cite

Effects of aminaftone 75 mg TID on soluble adhesion molecules: A 12-week, randomized, open-label pilot study in patients with systemic sclerosis

Cited by 15 publications

References 11 publications

Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon: A Feasibility Study

Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon: A Feasibility Study

Aminaphtone for Light Bleeding in Patients Under Oral Anticoagulation

Prevention of Excessive Endothelin-1 Release in Sclerotherapy

Contact Info

Product

Resources

About